ArticleFrontiers in medicine2026
Binasal occlusion for the non-invasive management of acute acquired comitant esotropia.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the clinical effectiveness of binasal occlusion (BNO) as a non-invasive treatment for acute acquired comitant esotropia (AACE) and to explore potential predictors of therapeutic response. Methods: This retrospective case series included 32 AACE patients who underwent BNO therapy for at least 6 months. Changes in ocular deviation angles, diplopia resolution, and binocular function were assessed before and after treatment. Patients were categorized into cured (orthophoria), effective [≥10 prism diopter (PD) reduction], and ineffective groups. Univariate and multivariate analyses were conducted to identify predictors of therapeutic success. Results: BNO significantly reduced ocular deviation. The median near deviation decreased from 25.00 PD (IQR 20.00-30.00) to 17.50 PD (IQR 5.50-33.75) ( Conclusion: BNO represents a promising, non-invasive intervention for AACE, particularly in cases with smaller deviations and early presentation. This case series provides preliminary evidence that BNO may reduce deviation and potentially lower surgical need. However, the absence of a control group precludes causal inference. Future randomized controlled trials with standardized outcomes are needed to confirm efficacy and define BNO's role in AACE management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.